Research programme: cancer therapuetics - Apros Therapeutics
Latest Information Update: 06 Oct 2020
At a glance
- Originator Apros Therapeutics
- Class Antineoplastics; Small molecules
- Mechanism of Action Toll-like receptor 7 agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Cancer
Most Recent Events
- 21 Sep 2020 Preclinical trials in Cancer in USA (unspecified route) before September 2020 (Apros Therapeutics pipeline, September 2020)